Compare Inovio Pharmaceuticals Inc (INO) vs Sirius XM Holdings Inc (SIRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Sirius XM Holdings Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Sirius XM Holdings Inc trades at $30.13 (market cap $10.30B). The key difference: Sirius XM Holdings Inc is far larger — about 115.4× Inovio Pharmaceuticals Inc's market cap, and Sirius XM Holdings Inc pays a 3.53% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SIRI | |
|---|---|---|
Market Cap | $89.27M | $10.30B |
Sector | Health | Media |
52-Week High | $2.87 | $31.22 |
52-Week Low | $1.05 | $19.92 |
Enterprise Value | $60.28M | $19.97B |
Dividend Yield | — | 3.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Sirius XM (SIRI) trades at $30.68, up 0.29% with a bullish technical signal and strong analyst support (58% buy ratings). The company shows improving fundamentals with three consecutive quarterly earnings beats and a return to profitability in 2025 after a 2024 loss. Recent developments include a strategic advertising partnership with YouTube and potential inclusion in the S&P MidCap 400 index.
The stock presents value characteristics with a P/E of 12.96 and P/B of 0.88, trading near the consensus price target of $31.17. Key risks include competitive pressures in media streaming and high debt levels despite recent improvement. Revenue stabilization and new partnerships provide catalysts, though execution risks remain in a challenging advertising environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Sirius XM Holdings Inc
SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →
